Argos Therapeutics Expands Global Patent Protection
September 06, 2012 08:01 ET
|
Argos Therapeutics
DURHAM, N.C., Sept. 6, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics to Present at the Stifel Nicolaus 2012 Healthcare Conference
September 04, 2012 12:45 ET
|
Argos Therapeutics
DURHAM, N.C., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial
July 02, 2012 08:00 ET
|
Argos Therapeutics
DURHAM, N.C., July 2, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the...
Argos Therapeutics Presents Positive Phase 1a Data for AGS-009 in Patients With Lupus at 2012 EULAR Congress
June 07, 2012 08:30 ET
|
Argos Therapeutics
DURHAM, N.C., June 7, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized and novel immunotherapies,...